Vaxart ( NASDAQ: VXRT ) provided business and cash runway updates as the company continues to advance its oral pill vaccine platform. Vaxart anticipates that net proceeds from the recent $40M offering, expected fees and reimbursements under its Project NextGen award of up to $453 million, combined with its existing cash, cash equivalents and investments, will extend its cash runway into 2026. Source: Press Release More on Vaxart Vaxart, Inc.
(VXRT) Q1 2024 Earnings Call Transcript Biggest stock movers today: ADBE, MSM, RH, and more Vaxart to raise $40M via stock offering Seeking Alpha’s Quant Rating on Vaxart Historical earnings data for Vaxart.
